ACTM-838

ACTM-838 is an engineered attenuated Salmonella Typhimurium (bacterial delivery, STACT platform) from Actym Therapeutics. An engineered, weakened Salmonella given into a vein that gathers in tumours and delivers two immune payloads there: an engineered IL-15 complex and a constitutively active STING. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry lists NCT06336148 as terminated: "Sponsor's strategic business decision". The company website still says ACTM-838 "is currently in a Phase 1a/b trial". Whether it works in people has not been established unless a trial below reports it.